PSMA-Avid Desmoid Tumor of the Abdominal Wall on 18F-Piflufolastat PET/CT-Reference-Cited by-同舟云学术

PSMA-Avid Desmoid Tumor of the Abdominal Wall on 18F-Piflufolastat PET/CT

Published:2024-05-09 Issue:7 Volume:49 Page:672-673
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Bommekal Siddharth¹,Flynt Lesley²,Tewari Sanjit Om²,Surasi Devaki Shilpa Sudha²

Affiliation:

1. Michael DeBakey High School for Health Professionals

2. Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Abstract

Abstract Prostate-specific membrane antigen (PSMA) PET/CT is widely used in the evaluation of suspected metastasis for initial definitive therapy and suspected recurrence of prostate cancer. We outline a case report of a 62-year-old man with history of prostate cancer treated with surgery, salvage radiation, and hormonal therapy presenting with rising PSA levels. There was incidental detection of a PSMA-avid subcutaneous abdominal wall mass on PSMA PET/CT study, which was consistent with desmoid fibromatosis on an ultrasound-guided biopsy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference15 articles.

1. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer;J Cell Biochem,2004

2. Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial;J Nucl Med,2020

3. Diagnostic performance of (18)F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study;Clin Cancer Res,2021

4. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY);J Urol,2021

5. Diagnostic performance and safety of positron emission tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE);Eur Urol,2023